David Lu

Practice Areas

David Lu is a partner in the firm’s Intellectual Property practice group. David focuses his practice on patent prosecution, strategic intellectual property counseling, and due diligence for life science industries. He has designed global patent strategies in the field of pharmaceuticals and biotechnology, and managed large patent portfolios for a variety of clients. David's clients range from international corporations, mid-sized biotech companies, to venture capital funded startups.

David has handled matters in numerous technology areas, including cancer therapies, genome technologies, gene therapies, antibodies and antibody-drug conjugates, mRNA technologies, siRNA drugs, personalized medicine, small molecules, diagnostic methods, medical devices, and laboratory instruments. By identifying each client's technology strengths and business goals, David provides customized and creative legal solutions.

Professional Memberships

Member, Boston Intellectual Property Law Association (BIPLA)

Member, National Asian Pacific American Bar Association (NAPABA)

Member, Asian American Lawyers Association of Massachusetts (AALAM)

Member, Duke Boston Regional Board

Leadership Councils, Health Care and Life Sciences, Greater Boston Chamber of Commerce

Publications

Co-author, Physiological modulation of endogenous BRCA1 p220 abundance suppresses DNA damage during the cell cycle. Genes Dev. 27(20): 2274-91. (2013)

Co-author, Further evidence for BRCA1 communication with the inactive X chromosome. Cell 128(5): 998-1002. (2007)

Co-author, Epstein-Barr Virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog. 2(3):e23. (2006)

Co-author, Kaposi’s sarcoma associated herpesvirus expresses an array of novel viral microRNAs in latently infected cells. Proc. Natl. Acad. Sci. U S A 102(15): 5570-75. (2005)

Co-author, Adenovirus VA1 non-coding RNA can inhibit small interfering and microRNA biogenesis and function. Journal of Virology 78(23): 12868-76. (2004)

Co-author, Nonsense mediated decay induced by tethered human UPF3B is restricted to the cytoplasm. RNA Biology 1(1): 42-47. (2004)

Co-author, Exon junction complexes mediate the enhancing effect of splicing on mRNA expression. Proc. Natl. Acad. Sci. U S A 100(20): 11327-32. (2003)

Co-author, Analysis of the stimulatory effect of splicing on mRNA production and utilization in mammalian cells. RNA 9(5): 618-30. (2003)

Education